Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen to Distribute MitoSciences' Antibodies and Immunoassays

NEW YORK (GenomeWeb News) – Invitrogen said today that it will become the exclusive North American distributor of all of MitoSciences products, which includes monoclonal antibodies and immunoassays for researching mitochondrial proteins and diseases.
Invitrogen said that as MitoSciences’ existing distribution agreements expire, it would take over those agreements worldwide on an exclusive basis. The firms did not disclose how many of those distribution agreements exist.
The pact will add more than 200 new products to Invitrogen’s antibody and kit catalog, the Carlsbad, Calif.-based firm said.
August Sick, vice president and general manager of Invitrogen’s Cellular Analysis Business Unit, said in a statement that Invitrogen plans to offer prepackaged kits in the future that will combine MitoSciences’ technology with its fluorescent labeling and cell separation technologies for mitochondrial research.
The firms did not disclose financial or any other additional terms of the alliance.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.